ACAD
26.76
-0.48
-1.76%
AEMD
4.81
+0.01
+0.21%
APRI
1.14
-0.06
-5.00%
ARNA
1.41
+0.04
+2.92%
ATEC
4.9
+0.02
+0.41%
CNAT
1.94
+0.03
+1.57%
CRXM
0.17
+0.00
+0.0589%
CYTX
1.6
+0.04
+2.56%
DXCM
65.01
+0.4
+0.62%
GNMK
10.96
-0.22
-1.97%
HALO
11.53
-0.1
-0.86%
ILMN
123.2
-0.28
-0.23%
INNV
0.259
-0.001
-0.44230%
INO
7.14
+0.01
+0.14%
ISCO
1.68
+0.17
+11.26%
ISIS
0
0.00
0.00%
LGND
104.48
+0.85
+0.82%
LPTN
2.615
+0.115
+4.600%
MBVX
3.97
+0.12
+3.12%
MEIP
1.58
+0.02
+1.28%
MNOV
7.17
-0.28
-3.76%
MRTX
5.9
+0.3
+5.36%
MSTX
0.122
+0.003
+2.6050%
NBIX
41.66
-0.05
-0.12%
NUVA
67.84
-0.15
-0.22%
ONCS
1.44
+0.13
+9.92%
ONVO
3.31
+0.01
+0.30%
OREX
2
+0.06
+3.09%
OTIC
18.15
+0.75
+4.31%
QDEL
23.04
+0.31
+1.36%
RCPT
0
0.00
0.00%
RGLS
2.5
-0.1
-3.85%
RMD
62.23
+0.86
+1.40%
SCIE
0.002
0.00
-9.6386%
SPHS
2.72
-0.03
-1.09%
SRNE
5.4
-0.05
-0.92%
TROV
2.5
-0.15
-5.66%
VICL
2.5
+0.04
+1.63%
ZGNX
12.15
-0.2
-1.62%
ACAD
26.76
-0.48
-1.76%
AEMD
4.81
+0.01
+0.21%
APRI
1.14
-0.06
-5.00%
ARNA
1.41
+0.04
+2.92%
ATEC
4.9
+0.02
+0.41%
CNAT
1.94
+0.03
+1.57%
CRXM
0.17
+0.00
+0.0589%
CYTX
1.6
+0.04
+2.56%
DXCM
65.01
+0.4
+0.62%
GNMK
10.96
-0.22
-1.97%
HALO
11.53
-0.1
-0.86%
ILMN
123.2
-0.28
-0.23%
INNV
0.259
-0.001
-0.44230%
INO
7.14
+0.01
+0.14%
ISCO
1.68
+0.17
+11.26%
ISIS
0
0.00
0.00%
LGND
104.48
+0.85
+0.82%
LPTN
2.615
+0.115
+4.600%
MBVX
3.97
+0.12
+3.12%
MEIP
1.58
+0.02
+1.28%
MNOV
7.17
-0.28
-3.76%
MRTX
5.9
+0.3
+5.36%
MSTX
0.122
+0.003
+2.6050%
NBIX
41.66
-0.05
-0.12%
NUVA
67.84
-0.15
-0.22%
ONCS
1.44
+0.13
+9.92%
ONVO
3.31
+0.01
+0.30%
OREX
2
+0.06
+3.09%
OTIC
18.15
+0.75
+4.31%
QDEL
23.04
+0.31
+1.36%
RCPT
0
0.00
0.00%
RGLS
2.5
-0.1
-3.85%
RMD
62.23
+0.86
+1.40%
SCIE
0.002
0.00
-9.6386%
SPHS
2.72
-0.03
-1.09%
SRNE
5.4
-0.05
-0.92%
TROV
2.5
-0.15
-5.66%
VICL
2.5
+0.04
+1.63%
ZGNX
12.15
-0.2
-1.62%
Home » Archive by Category

Xconomy

Amyloid Hypothesis Lives On—Solanezumab, Too, Despite “Siren Song”

December 9, 2016 – 11:41 am

When Eli Lilly (NYSE: LLY) reported the day before Thanksgiving, that its Alzheimer’s treatment solanezumab failed to significantly improve the condition of people with a mild form of the…

[[Click headline to continue reading.]]

Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More

December 9, 2016 – 4:30 am

What a week. The 21st Century Cures Act is now waiting President Obama’s promised signature after easy passage through Congress. President-elect Donald Trump re-stirred the drug-pricing pot…

[[Click headline to continue reading.]]

Craig Venter Used Own Posh Health Clinic To Diagnose His Cancer

December 8, 2016 – 5:17 am

Speaking at a conference in San Francisco Wednesday, geneticist Craig Venter revealed that he had just had surgery for prostate cancer three weeks ago. A health workup at his own high-end clinic,…

[[Click headline to continue reading.]]

Wake Up, Pharma—Trump Is Not Your Savior

December 7, 2016 – 10:01 pm

Since the election, leaders in biotechnology and pharmaceuticals are acting like they got away with robbery. The Nasdaq Biotechnology Index went up 9 percent overnight on November 8th. With Donald…

[[Click headline to continue reading.]]

Senate Approves 21st Century Cures Act, Sending Bill to Obama

December 7, 2016 – 2:32 pm

The U.S. Senate has voted overwhelmingly to approve the 21st Century Cures Act, a wide-ranging healthcare spending and reform bill that aims to infuse medical research with new funding and also speed…

[[Click headline to continue reading.]]

At Late-Night ASH Talk, Juno Execs Look Beyond Stalled “Rocket” Trial

December 6, 2016 – 5:41 am

Juno Therapeutics is still mulling next steps for its lead product, an experimental cancer immunotherapy now stuck in limbo because five of 68 adult leukemia patients in its current study, a clinical…

[[Click headline to continue reading.]]

ASH Roundup: CAR-T Shuffle, Hemophilia Updates, Checkpoint Progress & More

December 6, 2016 – 4:58 am

Two years ago at the American Society of Hematology conference, excitement, not blood, was running in the streets of San Francisco. The cancer immunotherapy known as CAR-T was the star of the show,…

[[Click headline to continue reading.]]

With Nod To Biden, Senate To Say Yes To “Cures” Spending, Reform Bill

December 5, 2016 – 5:31 pm

The U.S. Senate cleared the way for the 21st Century Cures Act, an omnibus healthcare spending and reform bill, by voting 85-13 to end debate this evening. It passed the House with 392 votes last…

[[Click headline to continue reading.]]

The Xconomy Immuno-Oncology Resource: A Mid-ASH T Cell Update

December 5, 2016 – 4:35 am

[Updated, 12/5/16, 4 p.m. See below.] If you’re following cancer immunotherapy, you might feel a bit swamped by this week’s wave of clinical data from experimental programs that turn…

[[Click headline to continue reading.]]

This Week in Drug Pricing and Post-Election Healthcare Policy News

December 2, 2016 – 7:50 am

Healthcare news has been coming fast and furious in the fallout of the election, particularly this week. Read on below for the latest on the 21st Century Cures Act, the Trump Administration’s latest…

[[Click headline to continue reading.]]